Skip to main content
Alkem Laboratories Limited logo

Alkem Laboratories Limited — Investor Relations & Filings

Ticker · ALKEM ISIN · INE540L01014 LEI · 335800GCAE5WIF4PSG69 BSE.NS Manufacturing
Open in API
Filings indexed 1,788 across all filing types
Latest filing 2026-05-18 Board/Management Inform…
Country IN India
Listing BSE.NS ALKEM

About Alkem Laboratories Limited

https://www.alkemlabs.com/

Alkem Laboratories Limited specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company’s portfolio covers a wide range of therapeutic areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients. It has also expanded into chronic therapeutic segments such as cardiology, diabetology, neurology, and dermatology. Alkem operates multiple manufacturing facilities and advanced research and development centers dedicated to formulation development and active pharmaceutical ingredients. The company provides branded generics, generic medications, and active pharmaceutical ingredients to various international markets. Its operations are supported by a robust supply chain and a focus on high-quality production standards to meet global regulatory requirements.

Recent filings

Filing Released Lang Actions
Please find Attached herewith Intimation regarding Appointment of Senior Management Personnel.
Board/Management Information Classification · 95% confidence The document is a formal announcement to stock exchanges under SEBI LODR Regulation 30 regarding the appointment of a senior management personnel (Mr. Chanakya Misra). It details the change in senior management and provides the requisite disclosures. This falls squarely under Board/Management Information.
2026-05-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a short notification letter from Alkem Laboratories Limited addressed to stock exchanges, informing about a US FDA inspection at the company's CRO facility. It states that no Form 483 was issued. The document is brief (1175 characters) and serves as an announcement of a regulatory event rather than a detailed report or financial filing. It does not contain financial data, management changes, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-08 English
This is to Inform you regarding US FDA inspection conducted today at the Company'' s CRO facility located at Taloja.
Regulatory Filings Classification · 92% confidence The document is a stock exchange filing notifying investors that the US FDA conducted an unannounced inspection at the company’s CRO facility and no Form 483 was issued. It is a regulatory compliance announcement to the exchanges, not a financial report, earnings release, or management change. It best fits the fallback category for general regulatory announcements (RNS).
2026-05-08 English
Please find Attached herewith Disclosure under Regulation 30 of SEBI(LODR) 2015.
Regulatory Filings
2026-05-05 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to timely disclosure of material events or information by listed companies. It reports a favorable Order-in-Appeal from a statutory authority regarding GST demand, including details of the order and its impact. The document is addressed to stock exchanges and is a regulatory announcement rather than a financial report or detailed analysis. The length is about 3063 characters, which is relatively short and consistent with a regulatory announcement. There is no financial statement or detailed financial analysis present. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-05 English
Please find attached herewith Intimation about US FDA Inspection at Company'' s manufacturing facility located at Amaliya, Daman.
Regulatory Filings
2026-05-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.